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Abbreviations  
 
ANOVA  : Analysis of Variance 
ARND  : Alcohol-Related Neurodevelopmental Disorder  
BW : Body Weight 
CE : Coefficient of Error 
cc  : Cubic centimetre 
Cel/bs : cerebellum/brainstem 
DNT : Developmental Neurotoxicity 
E/V : entorhinal/visual cortex  
FASD : Fetal Alcohol Spectrum Disorders 
FAS : Fetal Alcohol Syndrome 
FEA : Fetal Alcohol Effect  
[18F]FDG : [18Fluorine]Fluoro Deoxy Glucose 
F : frontal cortex  
FP : frontopolar cortex  
HSD  : Tukey's Honestly Significant Difference 
IBM SPSS : International Business Machines Statistical Package for the 
Social Sciences 
MA  : Motor Activity 
MBq : Mega Becquerel 
MCT1 : Monocarboxylate Transporter 1 
PEA  : Prenatal Exposure to Alcohol  
PET   : Positron Emission Tomography 
PND  : Postnatal Day  
OECD : Organization for Economic Cooperation and Development 
OPPTS : Office of Prevention, Pesticides & Toxic Substances 
REACH  : Registration, Evaluation, Authorisation and Restriction of 
Chemicals. 
ROI : Region of Interest 
Stria  : striatum  
SPF  : Specific Pathogen Free 
T/O/P : temporal/occipital/parietal cortex  
TG : Test Guideline 
Thal  : thalamus 
TOTDM : Total Distance Moved 
US-EPA  : United States Environmental Protection Agency 
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Abstract 
 
Little is known about the toxic effects of various chemicals on the unborn child during 
pregnancy, or about the role of prenatal exposure of ethanol on vulnerability for diseases later 
in life. Current preclinical reproductive toxicity tests in animals mainly focus on physical 
malformations of the newborn. However, ‘hidden effects’ of toxic compounds like 
dysregulation of neuronal development often remain undetected. Extensive neuropathological 
and behavioural tests have been issued, but these lack sensitivity and/or are very laborious 
and require many laboratory animals. As an alternative or supplemental test approach to 
conventional motor activity testing we investigated in rats the potential of functional [18F]FDG 
microPET brain imaging.  
F0-rats were exposed to ethanol (EtOH) 0%, 1.5%, 4.0%, 6.5% , 9.0%, 11.5%, 14.0% 
in drinking water from 14 days pre-mating to weaning of their litters (PND 21); F1-animals 
were further exposed up to sacrifice (PND 70±2) [TG OECD 433]. Brain weight and body 
weight were determined at several test ages as indicated in test guidelines for reproduction 
and developmental neurotoxicology. As an alternative or supplemental test approach to 
conventional motor activity testing –a test, also proposed in current test guidelines for 
toxicology- we investigated in rats the potential of functional [18F]FDG microPET brain imaging. 
Hereto, animals from three groups, i.e. 0%, 4.0%, 9.0% v/v EtOH, were selected for in vivo 
microPET imaging (N=5 female F1-rats/group; 1 rat/litter) and motor activity (MA) (N=10 
female F1-rats/group; 1 rat/litter). Cerebral [18F]FDG uptake was measured at PND 18, 21, 
35, 61 and analyzed with commercial available software (AsiPro); motor activity (MA) was 
assessed at PND 13, 17, 21, 60 and analyzed using Ethovision (Noldus, NL) software. Results 
of PET and MA were mutually compared as well as with the findings on brain and body weight 
measured in all dose groups.  
Regarding body weight (BW), the results demonstrated a dose related reduction in 
BW gain of F1-female animals which was significant for the 4.0%, 6.5%, 9.0%, 11.5% and 
14.0% EtOH groups from PND 28 onwards. In contrast, the 1.5% EtOH group showed a 
suggestively higher BW than the control group up to PND 21. The highest dose group (set on 
tap water from PND 21 onwards) demonstrated a ‘catch-up growth’ reaching on PND 70 a 
level near that of the 4.0% and 6.5% EtOH group, however, still differing significantly from the 
control group. Brain weight on PND 70 was found to be significantly decreased for the 9.0% 
and 11.5% EtOH dose groups compared to the control group. The highest 14.0% EtOH dose 
group –set on water from PND 21 onwards- recovered from the toxic effects of ethanol. Brain 
activity measured by [18F]FDG brain microPET imaging was depressed by ethanol in a dose-
related manner, significant (p<0.05) in the 9.0% EtOH group at PND 35 (striatum, thalamus, 
cerebellum/brain stem, midbrain, entorhinal/visual cortex, temporal/occipital/parietal cortex, 
hippocampus, frontal cortex) and PND 61 (striatum, thalamus, cerebellum/brain stem, 
hippocampus). Strikingly, at PND 21, the low dose of 4.0% EtOH tends towards increased 
[18F]FDG-activity in all regions of interest (ROI) analyzed. In some regions, this tendency (not 
significant) towards a biphasic effect, i.e. increase at low dose and reduction at high dose, 
seemed to be larger than in others, e.g. the hippocampus (p<0.1). Also motor activity was 
affected by ethanol, albeit not significantly. Over all, the pattern of activity in the 4.0% EtOH 
group resembled that of the control group; activity in the 9.0% EtOH group, however, showed 
tendency (not significant) towards hyper-activity on PND 17 and hypo-activity on PND 60. This 
hyper-activity seemed due to the fact that animals at this time point had difficulties to 
habituate. The hypo-activity (not significant) on PND 60 suggested a subtle overall decrease 
over the total test session; however, habituation was no longer impaired.  
Our results demonstrate that life cycle exposure to EtOH [TG OECD 443] caused a 
persistent defect in the young adult F1-animal. Suggestive (non significant) developmental 
and neurotoxic changes induced by ethanol in the first-generation offspring as detected by 
conventional motor activity testing using 10 rats/group, could be detected by [18F]FDG 
microPET imaging using a maximum of 5 rats/group only. These observations warrant further 
evaluation of PET imaging as a tool for developmental neurotoxicity studies. The rat model 
with EtOH may also serve to further unravel mechanisms underlying alcohol intoxication in 
humans. 
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Samenvatting 
 
Er is weinig bekend over de toxische effecten van verschillende chemicaliën op het 
ongeboren kind gedurende de zwangerschap, of over de rol van prenatale blootstelling van 
ethanol op de kwetsbaarheid van ziekten op latere leeftijd. Huidige preklinische reproductieve 
testen in dieren concentreren zich op fysieke misvormingen van pasgeborenen. Echter, 
‘verborgen effecten’ van toxische stoffen zoals ontregeling van de neuronale ontwikkeling 
blijft vaak onontdekt. Uitgebreide neuropathologische testen en gedragstesten zijn 
uitgevaardigd, maar missen de testgevoeligheid en/of zijn erg arbeidzaam en vereisen veel 
proefdieren. Als een alternatief of supplementaire testbenadering voor de conventionele 
motoractiviteit test hebben we het potentieel van functionele beeldvorming in het brein met 
[18F]FDG micro PET onderzocht 
F0-ratten werden blootgesteld aan ethanol (EtOH) 0%, 1.5%, 4.0%, 6.5% , 9.0%, 
11.5%, 14.0% in drinkwater vanaf 14 dagen voor het paren tot (einde van) zoogperiode van 
hun nakomelingen (postnatale dag 21; PND 21); F1-dieren werden verder blootgesteld tot 
opoffering (PND 70±2) [Testrichtlijn OECD 433]. Brein –en lichaamsgewicht werden 
vastgesteld op verscheidene testleeftijden zoals aangegeven in de testrichtlijnen voor 
reproductie en ontwikkelingsneurotoxiciteitsonderzoek. Als een alternatief of supplementaire 
testbenadering voor de conventionele motoractiviteit test –een test die ook in de huidige 
testrichtlijnen voor toxicologie is voorgesteld-  hebben we het potentieel van functionele 
beeldvorming in het brein van ratten met [18F]FDG micro PET onderzocht. Hiertoe zijn dieren 
van drie groepen geselecteerd, namelijk 0%, 4.0%, 9.0% v/v EtOH voor in vivo beeldvorming 
met micro PET (N=5 vrouwelijke F1-ratten/groep; 1 rat/nest) en motoractiviteit (MA) (N=10 
vrouwelijke F1-ratten/groep; 1 rat/nest). Cerebrale [18F]FDG opname werd gemeten op PND 
18, 21, 35, 61 en geanalyseerd met commercieel verkregen software (AsiPro); motoractiviteit 
(MA) werd vastgesteld op PND 13, 17, 21, 60 en geanalyseerd met behulp van Ethovision 
(Noldus, NL) software. PET en MA resultaten werden met elkaar vergeleken evenals met de 
bevindingen in het brein -en lichaamsgewicht die gemeten werden in alle dosisgroepen. 
De resultaten van lichaamsgewicht (BW) toonden een dosisgerelateerde reductie in 
de toename van lichaamsgewicht van de F1-vrouwtjes die significant was voor de 4.0%, 6.5%, 
9.0%, 11.5% and 14.0% EtOH groepen vanaf PND 28. De 1.5% EtOH group toonde 
daarentegen een suggestief hoger lichaamsgewicht dan de controle groep tot aan PND 21. 
De hoogste dosisgroep (die op water was gezet vanaf PND 21) vertoonde een ‘inhaalslag’ 
waarbij op PND 70 het lichaamsgewicht een waarde bereikte die vergelijkbaar was met de 
4.0% en 6.5% EtOH groep. Het lichaamsgewicht van de 14.0% EtOH groep was echter nog 
steeds significant lager ten opzichte van de controle groep. Breingewicht op PND 70 was 
significant lager voor de 9.0% and 11.5% EtOH dosisgroepen in vergelijking met de controle 
groep. De hoogste 14.0% EtOH dosisgroep -die vanaf PND 21 op water werd gezet- herstelde 
van de toxische EtOH-effecten. Breinactiviteit gemeten met behulp van beeldvorming met  
[18F]FDG microPET was verlaagd door ethanol op een dosisgerelateerde manier die significant 
was op PND 35 in de 9.0% EtOH groep (striatum, thalamus, cerebellum/hersenstam, 
middenhersenen, entorhinale/visuele cortex, temporale/occipitale/pariëtale cortex, 
hippocampus, frontale cortex) en PND 61 (striatum, thalamus, cerebellum/hersenstam, 
hippocampus). De lage 4.0% EtOH dosisgroep op PND 21 vertoont opvallend een 
toegenomen [18F]FDG-activiteit in alle geanalyseerde ‘regions of interest’ (ROI). In sommige 
gebieden leek deze niet-significantie tendentie groter richting een bifasisch effect, dat wil 
zeggen: toename bij lage dosis en reductie bij hoge dosis, bijvoorbeeld in de hippocampus 
(p<0.1). Motoractiviteit werd ook beïnvloed door ethanol, doch niet significant. In het 
algemeen was het activiteitspatroon van de 4.0% EtOH groep vergelijkbaar met dat van de 
controle groep; de activiteit in de 9.0% EtOH groep vertoonde daarentegen een tendentie 
(niet-significant) richting een hyperactiviteit op PND 17 en hypoactiviteit op dag 60. Deze 
hyperactiviteit zou te maken kunnen hebben met de verstoorde habituatie op PND 17. De 
hypoactiviteit (niet-significant) op PND 60 suggereerde een subtiel algehele afname over de 
de totale testsesse; echter, habituatie was niet langer verstoord. 
Onze resultaten tonen aan dat een levenscyclus blootstelling van EtOH [Testrichtlijn 
OECD 443] een persistent defect veroorzaakte in het jongwolwassen F1-dier. Suggestieve 
(niet signficante) ontwikkelings –en neurotoxische veranderingen geïnduceerd door ethanol in 
een eerste generatie nakomelingen zoals gedetecteerd door conventionele motoractiviteit 
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waarbij 10 ratten/groep worden gebruikt, kon ook door beeldvorming met  [18F]FDG micro 
PET gedetecteerd worden waarbij slechts 5 ratten/groep werden gebruikt. Deze bevindingen 
rechtvaardigen verdere evaluatie van beeldvorming met PET als een instrument voor 
ontwikkelingsneurotoxiciteitsstudies. Het rattenmodel met EtOH zou ook kunnen dienen om 
verder mechanismen te ontrafelen die ten grondslag liggen aan alcohol intoxicaties bij 
mensen. 
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Introduction 
 
Exposure to toxic substances in the environment and every day products significantly 
contributes to the incidence of chronic disorders in man. A number of chemicals is known to 
cause developmental neurotoxic effects and therefore the potency of the substance causing 
developmental neurotoxicity needs to be assessed. In recent years, increasing attention has 
been focused on improving methods for hazard identification and prediction of potential 
neurotoxic effects caused by these chemicals.  
 
Developmental neurotoxicology 
Children are more susceptible to neurotoxic effects from exposure to chemicals than 
adults, since the brain is still under development many years after birth (approximately till the 
age of 24). The neurotoxic effects can already occur at a very early stage of nervous system 
development due to immature detoxification mechanisms of the foetus compared to the adult 
brain (Coecke et al., 2006). Furthermore, the immature blood-brain-barrier (BBB) in an unborn 
child makes the brain more vulnerable. The exact time point of exposure is important for the 
impact of neurotoxic compounds. Since brain regions develop during a narrow time window, 
the functional and structural consequences of a neurotoxicant in children are depending on 
the timing of exposure. Therefore, the effects of toxic chemicals observed in foetuses and 
children are not observed to the same extent in adults (Rice and Barone S Jr, 2000; 
Kaufmann, 2003). Obviously, also the dose and duration of exposure play a role in the 
neurotoxic effect. 
 
Development of the nervous system (humans versus rodents) 
The development of the nervous system occurs through the interaction of several 
synchronized processes, some of which are completed before birth, while others continue into 
adulthood.  
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Figure 1: Nervous system development in humans and rodents. Hashed bars represent the time of origin 
for each brain structure. Solid bars represent time to structural development for each brain structure (Rice 
and Barone, 2000). Figure reproduced from Faustman et al., 2003. 
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In humans, by the age of 5, brain size is approximately 90% of the adult size (Lenroot 
and Giedd, 2006). Brain development of rodents and humans in general is similar on a timeline of 
respectively days versus weeks. In some cases there are differences between species in relative 
mass and volume of a specific structure. For example, the neocortex and visual system are 
relatively larger in humans, while -as expected- the relative mass of the olfactory system is larger 
in rats; after all, rats are nocturnal animals and depend on sense and smell, rather than vision 
which is poor. Figure 1 (Faustman et al., 1997) provides a broad overview of the neurogenesis in 
the major structures of the brain and spinal cord and depicts the time during foetal development 
when neurogenesis occurs in each structure; in other words, when the neurons which will 
eventually comprise that structure are born. Within each broad brain region, various nuclei and 
other substructures also develop according to a predictable timetable. Both the amount and 
temporal windows of neurogenesis vary within different regions of the rat and human brain. 
 
Alcohol abuse: structural and functional neurotoxicology 
In 1973 Jones and Smith first described the Fetal Alcohol Syndrome, a set of specific 
birth defects caused by high amounts of maternal alcohol consumption (Jones and Smith, 1973). 
At birth, children with FAS have a growth deficiency and facial dysmorphogenesis. Furthermore, 
FAS children suffer from damage to the developing brain. They show microcephaly and cortical 
thinning. The third criterion of FAS is central nervous system disorders, including mental 
deficiency. However, there are also children born to mothers with heavy alcohol abuse during 
pregnancy, who do not meet the criteria of FAS. These children lack the facial features of FAS and 
are labelled as having fetal alcohol spectrum disorders (FASD). 
The worldwide incidence of FAS in the general population is estimated at 0.97 cases per 
1,000 live births. This number is more than twenty times higher in the United States (1.95 per 
1,000) compared to Europe and other countries (0.08 per 1,000) (Abel, 1995). The incidence of 
Fetal Alcohol Effect (FEA), Alcohol-Related Neurodevelopmental Disorder (ARND), Fetal Alcohol 
Spectrum Disorders (FASD) and Prenatal Exposure to Alcohol (PEA) is less clear. Estimates of 1 
per 100 live births have been made (Sampson, 1997). 
A main problem is that still more than half of the women of childbearing age consume 
alcohol and that 11.5% of these women could be labelled as moderate or heavy drinkers. In 
addition, approximately 12% of women continue drinking alcohol during their pregnancy and 2% 
even reports binge or frequent drinking (Barry et al., 2009). Knowing these numbers, it is to be 
expected that the number of children born with alcohol related disorders will increase rather than 
decrease in the near future. This is not only a problem for these children but also for society, as 
the costs for each individual with FAS has been estimated at 2.0 million dollar (Lupton, 2004).   
In vivo quantitative magnetic resonance imaging (MRI) studies confirmed abnormalities in brain 
morphology in children prenatally exposed to alcohol and allowed more insight into subtle 
structural dysmorphology in these subjects in post mortem studies (Swayze et al., 1997; Sowell et 
al., 2001 and 2002). Microcephaly, disproportionally reduced basal ganglia volume, and 
abnormalities of the cerebellar vermis and corpus callosum were demonstrated by Archibald et al, 
2001; Mattson et al., 1996; Riley et al. 1995 and Sowell et al., 1996. 
Apart from the aforementioned structural effects, ethanol also (indirectly) affects the 
functioning of brain regions (Goodlet et al., 2001). Some of the harmful effects of prenatal alcohol 
exposure also may be associated with alcohol-induced disruption of the brain’s utilization of 
glucose. Glucose has several crucial functions in the body, including the brain. First, it serves as 
an energy source in all cells. Second, it is used in the production of various important types of 
molecules, including DNA and RNA building blocks (i.e., nucleic acids), fat molecules (i.e., lipids), 
certain hormones (i.e., steroids), and certain neurotransmitters.  
To enter cells from the blood and fulfil its functioning, glucose must cross the cell 
membrane. To this end, most mammalian cells contain specific glucose transporter proteins 
namely GLUT1 through GLUT7. The principal glucose transporter proteins of the brain are GLUT1 
and GLUT3. In cultured rat neurons and astrocytes, short-term alcohol exposure reduced cellular 
glucose uptake as well as the levels of glucose transporter proteins (Hu et al., 1995). Similarly, 
prolonged prenatal exposure of rats to alcohol reduced both glucose uptake and GLUT1 gene 
expression (Singh et al., 1992). Because of the central role that glucose plays in the body, alcohol-
induced changes in glucose transport have broad implications and must be considered as an 
important potential contributor to both growth deficiency and CNS damage associated with 
prenatal alcohol exposure (Goodlet et al., 2001). 
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With regard to adolescence, 20% of the youth between 12 and 17 years old drinks 
alcohol. In this group, 10% can be categorized as binge drinking and 3% are heavy drinkers 
(Substance Abuse and Mental Health Service Administration, 2004). Knowing that the brain still 
develops throughout the adolescent period (Markus et al., 1987; Sowell et al., 1999), this 
excessive alcohol consumption can have consequences on the development of these people. In 
fact, adolescence is a period of significant neuro-maturation, during which the brain’s efficiency is 
enhanced through increased myelination and selective removal of synapses (synaptic pruning) 
(Brown et al., 2000). In particular, the hippocampus and prefrontal cortex develop more actively in 
adolescence than in adulthood, and subcortical gray matter and limbic system structures (septal 
area, hippocampus and amygdala) increase in volume. At the same time, cortical structures such 
as the prefrontal cortex decrease in volume, perhaps as a result of synaptic pruning (DeBellis et 
al., 2000). Through this process, the prefrontal area becomes more efficient as it matures into 
adulthood and enhances the ability of the adult brain (relative to the adolescent brain) to execute 
such tasks as planning, integrating information, abstract thinking, problem solving, judgment, and 
reasoning. The brain maintains a high rate of energy expenditure to sustain this 
neurodevelopment during adolescence, not tapering off toward adult levels until about age 20 
years. Because the adolescent brain undergoes dynamic changes, it may be more susceptible to 
damage from alcohol than the relatively stable adult brain. This hypothesis is supported by 
findings of differential changes in neurochemistry, gross morphology, and neuro-cognitive function 
between adolescents and adults in both animal and human studies (Zeigler et al., 2005). 
 
Mandatory animal testing  
Brain development in children can be disturbed during pregnancy, as well as early and 
late childhood (Kaufmann, 2003). In order to protect the health of children, developmental 
neurotoxicity (DNT) studies are carried out focussing on structural (morphologic) and functional 
(behavioural) changes of the nervous system (Johnson et al., 2006). Therefore, international 
legislation has been developed to enforce mandatory preclinical experimental animal testing of 
chemicals and newly developed drugs prior to production and consumption. This legislation is 
documented in a number of test guidelines which include specific testing methods and safety 
rules to verify possible toxic effects. Examples of these guidelines are the US-EPA health effects 
test guideline OPPTS 870.6300 Developmental Neurotoxicity (DNT) study, the developmental 
neurotoxicity screening test OPPTS 870.8600, the OECD guideline 426 Developmental 
Neurotoxicity Study and the more recently finalized OECD guideline 443 for an Extended One 
Generation Reproduction Toxicology Study. These guidelines concern details in the choice of 
animal species, dosing period, testing period and endpoints, and criteria for evaluating the results 
are discussed (US-EPA 1998; Organisation for Economic Co-operation and Development (OECD), 
2007, 2011).  
 
A major obstacle for the DNT endpoints in the guidelines is not only the laborious and 
time-consuming nature of the tests, but also the fact that they require many laboratory animals. 
The amount of laboratory animals used for toxicological and other safety testing is eight percent of 
all animals whereas more than 60% thereof is used for reproduction- and developmental toxicity 
testing (Bremer and Hartung, 2004). On top of this, the new European Union chemicals 
legislation, REACH (2007), came into force on 1 July 2007. The REACH legislation requires the 
registration of risk management measures and safety information of chemicals that are produced 
or imported in > 1 ton quantities. As part of the REACH registration, reproductive toxicity data, 
including developmental neurotoxicity data in case of pesticides, should be provided by the 
producer. Over a period of 11 years approximately 30,000 chemicals should be registered under 
the REACH legislation, which will increase the number of laboratory animals together with the 
production costs for the introduction of new substances on the market tremendously. 
So, in addition to ethical aspects and public acceptance, economic and social problems 
call for the timely development and validation of in vitro alternatives and /or (new) in vivo animal 
friendly and animal saving technologies.  
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In vivo imaging and reduction, refinement and replacement of laboratory animals for 
Developmental NeuroToxicology (DNT) testing. 
The reduction of animal use has become a primary objective in the development of 
international legislation for testing of chemicals. The litter –and not the pup- is the biological test 
unit in DNT studies (US EPA, 2000), which causes a large increase in the amount of animals 
needed. This is enhanced by the fact that DNT effects need to be evaluated at various test ages. 
Therefore, an alternative non-invasive method to study the effect of a compound on the 
development of the brain is desired, so an animal can be followed over time, being its own control.  
 
The nervous system has unique morphological and functional features and, where other 
health effects are usually characterized by a single outcome, neurotoxicity can be seen by various 
effects. So, realistic in vitro modelling is difficult and it seems evident that a single in vitro test will 
not be able to cover the different aspects of DNT. Therefore various new in vitro tests will be 
necessary in order to predict the developmental toxic hazard of chemicals (Coecke et al., 2006). 
Still, even a battery of in vitro tests will not mimic the integrity of the brain as a whole. To 
accomplish that, non-invasive technologies should be applied in vivo. 
In vivo imaging techniques can be used to investigate the developmental changes of the 
brain over time. The ability to visualize structural as well as functional changes in a non-invasive 
manner is one of the key-abilities of imaging. It can be used in situations where physiological, 
functional and anatomical data are needed simultaneously. Several different visualizing 
techniques like micro positron emission tomography (microPET), micro computerized tomography 
(microCT), single photon emission computed tomography (SPECT), magnetic resonance imaging 
(MRI), functional magnetic resonance imaging (fMRI), magnetic resonance imaging microscopy 
(MRImicroscopy) and multidimensional imaging, each having their own field of application, are 
promising tools to reduce the number of experimental animals used in mandatory preclinical 
regulatory studies for prediction of the risk for disease development and for the protection of 
adverse effects by environmental exposure (Dow-Edwards et al., 2006; Beekman and van der 
Have, 2007). 
 
Positron Emission Tomography (PET): a promising technique 
PET imaging is one of the promising techniques, to evaluate toxic effects on the nervous 
system. Until recently, its application was limited to humans due to the low resolution and the 
specific design of the instruments. The breakthrough of PET in clinical patient care has been the 
impetus for the development and spread of imaging in laboratory animals. PET tracers are 
commercially available now and distribution networks have been established, thereby diminishing 
infrastructure costs. New, more sensitive scanners have been built specifically for small animal 
imaging: the microPET (Chatziioannou et al., 1999). These newer instruments have improved 
resolution capabilities down to approximately 1 mm (Myers et al., 2001). This, combined with the 
fact that almost every drug can be labelled with a PET tracer and can be quantified accurately in 
vivo, gives PET a leading role in the preclinical evaluation of new drugs (Meikle et al., 2006).  
 
PET in combination with the tracer 2’-[18F]fluoro-2’-deoxyglucose (FDG) allows 
monitoring of brain glucose metabolism which is a surrogate biomarker measure for brain activity. 
Therefore, microPET can provide information about functionality in various regions of interest in 
the rat brain. Since [18F]FDG PET can measure the changes in brain activity directly in the affected 
region, the influence of external factors and thus the inter-individual variation in the 
measurements are expected to be lower than in behavioural tests. Consequently, sufficient 
statistical power could be reached with a smaller number of animals. 
PET imaging is a non-invasive technique and therefore permits the possibility for 
repeated measurements of the same animal over time. Hereby, information about the underlying 
mechanisms of early onset of the disease becomes available, which is of use in the search for 
new drugs. Statistical power is augmented by the collection of longitudinal data and by the fact 
that each animal to be studied serves as its own control. Both efficacy as well as the safety testing 
of new drugs and chemical exposure can be non-invasively tested at early onset and at different 
time points during exposure to potential toxic compounds. When proven feasible, implementation 
of non-invasive imaging techniques into the guidelines of DNT testing could save a tremendous 
amount of time, money and laboratory animals worldwide (Pogge et al., 2004; Schiffer et al., 
2007). 
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Motor activity in current DNT guidelines versus new microPET imaging technique 
Apart from the promising beneficial effect of microPET on the three R’s (reduction, 
refinement and replacement), there is another reason to further evaluate the potential role of 
functional PET imaging. In current DNT guidelines repeated motor activity assessment is proposed 
as an apical test; the test addresses more than just locomotion (e.g. habituation, arousal, anxiety 
and even learning and memory). Unfortunately, to reach statistical power, a minimum of 10 
animals per group is needed for testing and since the litter –and not the animal– is the biological 
unit, this requires many animals. Moreover, the sensitivity and interpretation of motor activity are 
subject to debate (Li, 2005). For example, differences in body weight or body temperature do not 
have to be directly related to neuronal toxicity; they may, however, influence locomotion. This way, 
these indirect effects can result in false conclusions.  
 
In 2005, Li stated in a review paper about the data evaluation for risk assessment in 
regulatory DNT testing, that it is important to recognize that many DNT guideline tests are apical 
tests that evaluate function during development. However, the effects on these apical tests (such 
as motor activity (MA)) can result from various direct and indirect effects on the nervous system 
and therefore, it often remains unclear what the biological basis of an observed effect on motor 
activity is in terms of developmental processes of the nervous system (neurogenesis, myelination, 
apoptosis). As long as we do not comprehend the total biological basis of the motor activity, the 
risk assessment of MA assessment data should be guided by our understanding of the strengths 
and limitations of this test (Li, 2005). 
 
So, apart from the fact that functional tests like MA assessment for DNT are laborious, 
expensive and require many animals, the design and relevance is also still a matter of debate. 
MicroPET could potentially provide more accurate, specific and additional information and in this 
study we will therefore link the MA assessment data with the microPET data. We hypothesize that 
microPET may add relevant information on toxic impact of early environmental exposure of the 
developing brain and so may (in time) replace (part of) the behavioral endpoints as indicated in 
current guidelines for DNT (US-EPA OPPTS 6300, 8600; OECD 426). 
 
Application of microPET in the present study 
In the study presented here the potential and relevance of non-invasive [18F]FDG brain 
microPET imaging for (regulatory) developmental neurotoxicity testing has been assessed in a 
regulatory study performed according to the new OECD guideline 443 for a so called extended one 
generation reproduction toxicology (EOGRT) study (OECD, 2011) using ethanol as a model 
chemical agent . Primary aims of this study were: 
1) to investigate whether developmental neurotoxicity induced by prenatal exposure to a 
chemical can be detected in first generation offspring using [18F]FDG brain microPET 
2) to assess the relevance of [18F]FDG brain microPET for regulatory developmental 
neurotoxicity testing to add on (or replace) endpoints for neuro-behaviour proposed in 
current guidelines (US-EPA OPPTS 870.6300, 8600; OECD 426 and OECD EOGRTS). 
Hereto, special attention was paid to conventional motor activity testing as proposed in 
these guidelines and the results compared with those obtained with the new technology of 
[18F]FDG brain microPET imaging. Further support was gathered from brain and body 
weight measurements. 
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Methods 
 
Test substance 
Ethanol (EtOH) (CAS Reg. no. 64-17-5) was obtained from Nedalco BV., The Netherlands  
 
Test system 
One hundred fourteen nulliparous female and 114 male rats, Wistar outbred (Crl:[WI]Wu 
BR), aged 9 and 8 weeks respectively, were obtained from a colony maintained under SPF 
conditions at Charles River Deutschland, Sulzfeld, Germany. At the start of the mating period the 
females and males were approximately 13 and 12 weeks old, respectively. A subset of F1-animals 
from different litters was transported from the animal facility of TNO to the animal facilities of the 
University Medical Centre Groningen for PET imaging. Dam and litter were kept together during 
transportation.  
 
Exposure 
Pregnant rats were exposed orally to ethanol (EtOH) via a life cycle exposure protocol as 
proposed in the OECD TG 443 (OECD, 2011). This means that the F0-females were dosed with 
EtOH 14 days before mating to weaning of the offspring (F1-animals, postnatal day 21 (PND 21)). 
Also F0-males were dosed during the period prior to and during mating. The F1-animals were 
exposed from weaning to termination (PND 70 ± 2). EtOH was administered via the drinking water 
ad libitum in 6 doses and 1 control group (n=10/group; 1/sex/litter): 0, 1.5%, 4.0%, 6.5%, 9.0%, 
11.5% and 14.0% v/v. The oral route of exposure was used, since human exposure to alcohol also 
occurs via drinking. No other source of drinking water was available to the animals. Control 
animals received normal tap water. The highest dose (14.0% v/v EtOH) was set on tap water from 
postnatal day 21 onwards because of poor health.  
 
Body weight 
F1-generation: The body weight of the female F1-animals of all groups (n=10/group; 
1/sex/litter) was measured at different time points during experimentation. During lactation 
animals were weighed twice a week, starting on PND 1, until PND 21 (PND 1, 4, 7, 10, 14, 17 and 
21). From PND 21 animals were weighed weekly. 
 
Brain weight  
Brain weight of female F1-animals of all groups (n=10/group; 1/sex/litter) was 
determined at sacrifice on PND 21 (weaning) and 70 (study termination). 
 
Motor Activity assessment (MA) 
Changes in spontaneous motor activity (MA) were assessed on PND 13, 17, 21 and 60 
using an automated quantitative microprocessor-based video image analysis system (Ethovision 
version 2.3). Rats were placed centrally and individually in 50 x 50 x 50 cm (l x w x h) black open 
roofed cages equipped with a video camera placed above the test cage. The position of the rat 
was continuously monitored throughout the test session. Spontaneous motor activity was 
expressed as Total Distance Moved (TOTDM). To study habituation, the 30 minute test session 
was divided in 5 time intervals of 6 minutes each and activity per time interval assessed. For 
comparison purposes with the results of [18F]FDG brain PET imaging results of similar groups were 
selected from the MA data and presented here, i.e. female F1-animals from dose-groups 0%  
(control group), 4.0% and 9.0% EtOH (n=10/group; 1/sex/litter) . 
 
[18F]FDG brain MicroPET 
MicroPET imaging was performed on PND 18, 21, 35 and 61. For microPET – to keep it 
manageable – two dose groups and a control group were selected from the dose range used in 
the main study, i.e. 0% (drinking water), 4.0% and 9.0% ethanol in drinking water. Choice for these 
dose groups was based on the results of body weight and ethanol/water intake in the main study, 
i.e. we expected little if any effect in the 4.0% group, and mild to moderate effects in the 9.0% 
group. Monitoring of clinical signs of animals of all dose groups in the main study (not shown) 
confirmed that EtOH-induced symptoms (e.g. thinness, paleness, weakness, dehydration) were 
predominantly observed in the highest EtOH dose groups (i.e. 11.5% and 14.0% EtOH groups) 
(Rianne Nederlof, personal communication). In principle, five animals per group (1/sex/litter) were 
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used for repeated PET imaging. Due to inappropriate dosing (in bladder) some measurements 
were useless and so, actual numbers (N) per test day were: control group, PND 18: N=4; PND 21: 
N=5; PND 35: N=3, and PND 61: N=4. The EtOH 4.0% group, PND 18: N=5, PND 21: N=5; PND 
35: N=4, and PND 61: N=5. The EtOH 9.0% group, PND 18: N=4, PND 21: N=5; PND 35: N=4, and 
PND 61: N=4.  
[18F]FDG was administered intraperitoneally (i.p.) to the rats and functioned as a tracer 
to measure brain activity. FDG is labeled with the isotope fluoro-18. This isotope has a half-life 
time of 110 minutes. It was prepared on site at the department of Nuclear Medicine and 
Molecular Imaging of the UMC Groningen, using a cyclotron. The pups were i.p. injected with 
approximately 20 MBq [18F]FDG and placed in the darkness in the open arena of a black open 
roofed cage - such as used for motor activity testing -  with monotonous background noise. This 
created the situation, in which the tracer distribution could take place in conscious –i.e. active– 
animals. After 45 minutes, the animals were anaesthetized with 5% isoflurane gas in medical air 
and positioned in a small animal dedicated PET camera (Siemens/Concorde MicroPET Focus 220) 
with the brain in the center of the field-of-view. At the center of the field-of-view, the spatial 
resolution of the PET camera is 1.35 mm. Anesthesia was maintained with 2% isoflurane in 
medical air until the end of the PET procedure. A 20-minute static emission scan was acquired, 
starting 50 min after tracer injection. Thereafter, a transmission scan was performed using an 
external 57Co point source. The transmission scan lasted 5 minutes and was used for correction of 
attenuation and scatter of radiation by the tissue within the animal and the camera bed (de Vries 
et al. 2008; van Waarde et al. 2008). Animals from the two EtOH groups and the control group 
were scanned in alternating order. After completion of the transmission scan, the animals were 
allowed to wake up from anesthesia and were returned to their home cage in a quarantine area of 
the animal facilities. The data were reconstructed using an iterative reconstruction algorithm (two-
dimensional Ordered-Subsets Expectation Maximization, OSEM 2D, 4 iterations) and were 
corrected for decay, attenuation, scatter and random coincidences. The final datasets consisted 
of 95 slices with a slice thickness of 0.8 mm, and an in-plane image matrix of 128 x 128 pixels of 
a 1 x 1 mm size. PET image analysis was performed using standard software (AsiPro VM 6.6.2.0; 
Siemens CTI Concorde Microsystems, LLC, 06/07) especially developed to analyze microPET data. 
The regions of interest (ROI) were drawn in individual coronal brain slices and converted to 
volumes of interest (VOI). Then, for each VOI the FDG uptake was calculated in MBq/cc and 
corrected for injected tracer dose and body weight to obtain a standardized uptake value (SUV). 
The SUV is defined as: 
 
 
 
 
It is assumed that 1 cm3 of brain tissue equals 1 g.  
In order to identify as much (general) structures as possible, the neuro-anatomy atlases of Paxinos 
and Watson (1986) and Palkovits and Brownstein (1988) were used. Comparison with the 
pictures in these atlases of systemic sections through the rat brain is considered a good method 
to recognize and define structures in the brain (De Groot et al., 2005). The rationale of defining 
the brain regions was based on technical feasible aspects, namely: the specific anatomical 
information from the atlas, combined with the information about the a-specific general metabolic 
activity and the spatial positioning in the PET images provided by the software (AsiPro VM 6.6.2.0; 
Siemens CTI Concorde Microsystems, LLC, 06/07), was used to identify specific regions of interest 
in the PET images. This led to nine definable regions of interest (ROIs): striatum, thalamus, 
cerebellum/brain stem, midbrain, entorhinal/visual cortex, temporal/occipital/parietal cortex, 
hippocampus, frontal cortex and frontopolar cortex. Absolute and relative values of brain regions 
were estimated.  
 
Statistics 
Statistical analysis was performed using programs on the Statistical Analysis System 
(SAS 9.1.3 or SAS 8.02e) for body and brain weights and IBM SPSS 20 for PET and MA 
assessment. Results of body and brain weight, PET and MA are presented as mean±SEM or, in 
case otherwise, it is mentioned. Homogeneity of the variances was tested according to Levene. 
Differences between groups, and the origin of possible differences, were tested with one-way 
analysis of variance (one way ANOVA) followed by Dunnett post-hoc test (equal variances) for body 
 Tissue activity concentration (MBq/g) x Body Weight (g) 
SUV= 
   Injected dose (MBq) 
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and brain weight and Tukey HSD post hoc for PET and MA. In case of unequal variances, Kruskall 
and Wallis test was used, followed by Williams unpaired T-test for body and brain weight, PET and 
MA. A two-way repeated measures ANOVA (i.e. mixed ANOVA) with Tukey HSD post-hoc (group) and 
Bonferonni post-hoc (time) was used to test habituation for MA measurements. 
 A significance level of p<0.05 (two-sided) was used for body and brain weight, PET and 
MA. In principle we described significant differences from the control group. As information from 
body and brain weight –with more dose levels- indicated hormetic effects (Calabrese and Baldwin, 
2003), we also reported for MA and PET significant differences (p<0.05) between the 4.0% and 
9.0% EtOH groups. For completeness, these results of body and brain weight are included in this 
article. 
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Results 
 
Body weight [Figure 2] 
During lactation, a dose related reduction in body weight gain of F1-female animals 
exposed to EtOH was observed in comparison to the control group, which was significant for the 
9.0%, 11.5% and 14.0% EtOH groups. Body weight gain in the 1.5% EtOH group, however, rather 
showed an increase (not significant) on PND 4, 7, 11, 14, 17 and 21. From PND 28 onwards, a 
dose-related reduction in body weight gain continued to exist (significant for the 4.0% EtOH, 6.5% 
EtOH,  9.0%, 11.5%, 14.0% EtOH groups). The highest dose group (set on tap water from PND 21 
onwards) demonstrated a ‘catch-up growth’ reaching on PND 70 a level near that of the 4.0% 
EtOH group, however, still differing significantly from the control group. The 4.0% EtOH group 
continued to have a significantly reduced body weight gain compared to the control group from 
PND 28 onwards (p<0.05). For the 9.0%, 11.5% and 14.0% EtOH groups this was the case in time 
period PND 14-70 (p<0.05) (i.e. Figure 2A and 2B).  
 
 
 
 
  
Figure 2: Differences in body weight of female F1-animals due to the toxic effects of life-cycle ethanol (EtOH) intake. 
[A] Dose-related decrease in body weight significant for the 9%, 11.5% and 14% EtOH groups; however, a suggestive 
increase (not significant) was observed in 1.5% ethanol group. [B] Dose-related decrease in body weight significant for 
the 4.0%,, 6.5%, 9.0%, 11.5%, 14.0% EtOH groups. Notice that the 14.0% EtOH group was set on tap water from PND 
21 onwards and showed ‘catch-up growth’. N=10/group/test age, 1/sex/litter. Statistical key: ANOVA/Dunnett, *, 
p<0.05, significant.  
 
Brain weight [Figure 3] 
In this study we assessed brain weight on postnatal day 21 as well as on PND 70. On 
PND 70, significantly decreased brain weight was observed for the 9.0% and 11.5% EtOH dose 
groups (p<0.05) compared to the control group. The highest 14.0% EtOH dose group –set on 
water from PND 21 onwards- recovered from these toxic effects of ethanol. On PND 21 already a 
tendentious change (not significant) towards reduced brain weight was observed in the highest 
dose groups.  
2B 2A 
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Figure 3: Differences in brain weight of female F1-animals due to the toxic effects of life-cycle ethanol (EtOH) intake.  
[A] On PND 21 no significant differences were observed, although a tendency towards reduced brain weight with 
increasing dose of EtOH was observed. [B] On PND 70 a significant reduction in the 9.0% and 11.5% ethanol group 
(p<0.05) compared to controls was found. Notice that the 14.0% EtOH group was set on tap water from PND 21 onwards 
and showed ‘catch-up growth. N=10/group/test age, 1/sex/litter Statistical key: ANOVA/Dunnett, *, p<0.05, significant. 
 
 
[18F]FDG microPET [Figure 4-6 and Table 1] 
Brain activity was assessed on postnatal day (PND) 18, 21, 35 and 61 in a control 
group and two EtOH dose groups (0% v/v, 4.0% v/v and 9.0% v/v EtOH); five animals per group 
were used. Regions of interest (ROI) were the frontopolar cortex, frontal cortex, 
temporal/occipital/parietal cortex, entorhinal/visual cortex, striatum, thalamus, midbrain, 
hippocampus and cerebellum/brain stem (See figure 4). 
 
 
 
 
Figure 4: [18F]FDG brain MicroPET determination of region(s) of interest (ROI) (coronal scans through rat brain from 
anterior to posterior): (1) frontopolar cortex, (2) frontal cortex, (3) striatum, (4) thalamus, (5) hippocampus, (6) 
temporal/occipital/parietal cortex, (7) midbrain, (8) entorhinal/visual cortex, (9) cerebellum/brain stem. MicroPET 
images derived from a male control (untreated) Wistar rat.  
 
 
3A  3B 
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In figure 5 the average [18F]FDG uptake in total brain is shown. In the control group a 
typical pattern of [18F]FDG uptake is observed over time: the uptake, as a measure of brain 
activity, decreases between PND 18 and PND 21 where after the uptake increases between PND 
21 and PND 35. From PND 35 to PND 61 we see a decrease in uptake again. This overall time 
pattern in [18F]FDG uptake was observed in all individuals of the control group. 
 
 
 
Figure 5: Effects of life-cycle exposure to ethanol (EtOH) on mean [18F]FDG uptake in total brain (i.e. the summation 
of the mean [18F]FDG uptake in the 9 brain regions divided by that number). Wistar female rat EtOH dose groups and 
controls (F1-generation). Number of animals (N) in the control group, PND 18: N=4; PND 21: N=5; PND 35: N=3, and 
PND 61: N=4; in the EtOH 4.0% group, PND 18: N=5, PND 21: N=5; PND 35: N=4, and PND 61: N=5; in the EtOH 
9.0% group, PND 18: N=4, PND 21: N=5; PND 35: N=4, and PND 61: N=4. 1/sex/litter. Statistical key: 
Anova/posthoc Tukey. *, p<0.05. On PND 21 the 4.0% EtOH group demonstrated tendency towards increase in total 
mean [18F]FDG uptake compared to 9.0% EtOH (p=0.098). Dose-related decrease in total mean [18]FDG uptake 
which reached significance for the 9% EtOH group (PND 35 (p<0.05); PND 61 (p=0.060). 
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[18F]FDG uptake in brain regions by EtOH-exposed F1-females 
Figure 6: Effects of life-cycle exposure to ethanol (EtOH) on mean [18F]FDG uptake in different brain regions. Wistar female rat EtOH dose groups and controls (F1-generation). Regions are ordered from the 
front of the brain (upper left) to the back of the brain (lower right). Number of animals (N) in the control group, PND 18: N=4; PND 21: N=5; PND 35: N=3, and PND 61: N=4; in the EtOH 4.0% group, 
PND 18: N=5, PND 21: N=5; PND 35: N=4, and PND 61: N=5; in the EtOH 9.0% group, PND 18: N=4, PND 21: N=5; PND 35: N=4, and PND 61: N=4. 1/sex/litter. Statistical key: Anova/posthoc Tukey. 
*, p<0.05. Dose-related decrease in [18]FDG uptake in all brain regions on PND 35  (significant, except frontopolar cortex, for the EtOH 9.0% group (p<0.05) and on PND 61 (significant for the 9.0% 
EtOH group in striatum, thalamus, hippocampus, cerebellum/brain stem (p<0.05). No significant differences between 4.0% EtOH group and controls were found albeit that on PND 21 a tendency (not 
significant) towards hyperactivity in the hippocampus (p=0.099). 
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Same pattern over time is observed in the different regions analyzed (Figure 6), 
although, in absolute terms, the uptake may differ between regions.  
Table 1 summarizes [18F]FDG uptake in the brain for the different test ages PND 18, 21, 
35 and 61 and the results of the statistical comparisons between the groups. 
On PND 18, no significant differences were found between the two EtOH dose groups 
and the control group. On PND 21 an increased activity is observed for the EtOH 4.0% group in the 
hippocampus compared to controls (0.5<p<0.1) and the 9.0% EtOH in striatum, thalamus, 
hippocampus, temporal/occipital/parietal cortex, midbrain and cerebellum/brain stem 
(0.5<p<0.1). On PND 35, the reduction of [18F]FDG-activity by EtOH is most pronounced; all brain 
regions, except the frontopolar cortex (p=0.051), show a significantly reduced activity in the EtOH 
9.0% group (p<0.05). Also in the 4.0% EtOH group activity is reduced but does not reach a preset 
level of significance. On PND 61 [18F]FDG-activity in the brain is normalizing although still showing 
reduced activity in the hippocampus, striatum, thalamus, cerebellum/brain stem (p<0.05) and 
also – although not significantly- in the frontopolar cortex (p=0.094), midbrain (p=0.087) and 
entorhinal/visual cortex (p=0.085). 
Together, the results on [18F]FDG microPET suggest that the effects of ethanol are most 
pronounced on PND 35 although still showing (persistent) reduction of brain activity on PND 61. 
This reducing effect of EtOH is also observed in the 4.0% EtOH group at these test time points. 
 
 
 
Table 1. Results of statistical evaluation of the effects of lifecycle exposure to 4.0% and 9.0% EtOH 
on [18F]FDG brain PET in female F1-rats  
ROI   PND 18   PND 21   PND 35  PND 61  
  EtOH 4.0% 9.0%  4.0% 9.0%  4.0% 9% 4.0% 9.0% 
FP  - -  ↑  -  ↓ ↓  - ↓  
F  - -  ↑  -  ↓ ↓* - ↓  
Stria  - ↓   ↑  -  ↓ ↓* ↓ ↓* 
Thal  - ↓  ↑  -  ↓ ↓* ↓ ↓* 
Hippo  - ↓  ↑  -  ↓ ↓* ↓ ↓* 
T/O/P  - ↓  ↑  -  ↓ ↓*  ↓ ↓  
E/V  - -  ↑  -  ↓ ↓* ↓ ↓  
midbrain - -  ↑  -  ↓ ↓* ↓ ↓  
Cel/bs  - -  ↑  -  ↓ ↓* ↓ ↓* 
 
Statistical key: one-way ANOVA/posthoc Tukey; significance levels:  *, p<0.05. Number of animals 
(N) in the control group, PND 18: N=4; PND 21: N=5; PND 35: N=3, and PND 61: N=4; in the EtOH 
4.0% group, PND 18: N=5, PND 21: N=5; PND 35: N=4, and PND 61: N=5; in the EtOH 9.0% group, 
PND 18: N=4, PND 21: N=5; PND 35: N=4, and PND 61: N=4. 
 
-, no change in activity compared to control group; ↓ / ↑, activity decreased / increased compared to 
control group.  
 
*, significantly different from control group. 
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Motor Activity (MA) assessment [Figures 7/8 and Table 2] 
 Figure 7 shows the activity pattern of Total Distance Moved (TOTDM) per 30min test 
session per test day (PND 13, 17, 21, 60) for all groups. In the control group TOTDM is relatively 
low on PND 13 (range 17-373 cm) and relatively high on PND 17 (range 732-7062 cm). On PND 
21, TOTDM (range 739-2702 cm) is higher than on PND 13 but lower than on PND 17. Highest 
values for TOTDM, however, are found on PND 60 (range 3101-5257 cm). Animals at PND 60 are 
larger in size and take larger steps during locomotion, leading to a larger DM/step, contributing to 
a larger TOTDM for the rats at age PND 60. It should be borne in mind, however, that rats of this 
strain –in fact– are most active on PND 17 compared to age 13, 21 and 60 (Historic data TNO; 
Didima de Groot, personal communication). 
 
 Table 2 summarizes for the different test ages PND 13, 17, 21 and 60 the results of the 
statistical comparisons between groups. Significant differences between groups are not observed 
at any of the 4 test-ages, albeit that in the 9% EtOH group compared to the 4.0% EtOH group a 
tendentious increased and decreased activity is found at PND 17 and PND 60 respectively. 
 
 
 
Figure 7:  Mean total distance moved in the arena (cm) for test days PND 13, 17, 21 and 60. Wistar female rat EtOH 
dose groups and controls (F1-generation). Life cycle exposure to 0% (control) or 4.0% and 9.0% EtOH in drinking water 
ad libitum from 2 weeks pre-mating to PND 70. N=10/group/day, except on PND 60 (4% EtOH group: N=9). Statistical 
key: Anova/Tukey post hoc. No significant differences between groups are observed. The suggestive increased activity at 
PND 17 and reduced activity at PND 60 in the 9% EtOH group compared to the 4.0% group is not significant (p>0.13). 
 
 
 
 
 
Table 2. Results of statistical evaluation of the effects of lifecycle exposure to 4.0% and 9.0% EtOH 
on motor activity in open arena in female F1-rats. 
  PND 13   PND 17   PND 21  PND 60  
EtOH  4.0% 9.0%  4.0% 9.0%  4.0% 9.0% 4.0% 9.0% 
TOTDM  ↑ -  ↓ ↑   ↑ ↑ ↑ ↓  
 
Statistical key: one-way ANOVA/posthoc Tukey, significance levels:  *, p<0.05; N=10/group/day, 
except on PND 60 (Group EtOH 4.0%: N=9) 
 
-, no change in activity compared to control group; ↓ / ↑, activity decreased / increased compared to 
control group. 
 
Significances compared to control group did not reach a level of significance.  
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Figure 7 shows the motor activity over the 30min test session of the control, EtOH 4.0% 
and 9.0% groups on PND 13, 17, 21 and 60. The control group displays habituation on all four 
test days. On PND 21 and PND 60, both EtOH groups show similar activity and similar 
(habituation) pattern as the control group. On PND 13, the mean values for TOTDM during the first 
two intervals are high for the EtOH 4.0% group, although not significantly different from the control 
group (notice large variation (i.e SEM-bars) in this group during these intervals). On PND 17, the 
EtOH 9.0% group shows impaired habituation (increased activity (not significant) in the fifth 
interval compared to control group (p=0.087). During the 3rd interval the activity between the two 
ethanol groups differs significantly (p<0.05). 
Results on motor activity, taken together, suggest that the hyperactivity observed in the 
9.0% EtOH group on PND 17 is due to the fact that animals at this time point have difficulties to 
habituate. The tendencious hypoactivity on PND 60 (compare Fig. 7) is likely represented by an 
overall tendency towards reduced TOTDM over the total test session, but habituation is no longer 
affected. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Effects of life cycle exposure to EtOH on motor activity of female Wistar F1 rats. Distance moved in the arena (cm) 
during 5 consecutive time intervals (of 6 minutes each) per total of 30 minutes test period for control (0% EtOH), 4.0% and 
9.0% EtOH dose groups on PND 13, 17, 21 and 60 respectively. Life cycle exposure to EtOH in drinking water ad libitum 
from 2 weeks premating to PND 70. N=10/group/test age, 1/sex/litter; except on PND 60 Group EtOH 4.0%: N=9. 
Statistical key: Mixed Anova/post hoc Bonferroni (time interval) and/or Tukey HSD post hoc (exposure group). *, p<0.05. 
Grey indicates differences between the 4.0% EtOH and 9.0% EtOH group (p<0.05). 
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Discussion 
 
FDG PET allows monitoring of brain glucose metabolism as a surrogate biomarker for 
brain activity. MicroPET can provide information about functionality in various regions of interest 
(ROI) in the rat brain. Here we demonstrated that, using [18F]FDG brain PET imaging, changes over 
time during normal development can be detected in the control group as well as developmental 
neurotoxicity induced by lifecycle exposure to ethanol (EtOH) in the first generation offspring by 
[18F]FDG brain PET imaging. A dose-dependent EtOH-induced significant reduction in average 
[18F]FDG uptake in total brain over time was observed in particular at PND 35 which still existed at 
PND 61 as a tendency towards significance. To our best knowledge, comparable studies with 
EtOH exposure in an Extended One Generation Reproduction Toxicology study were not published 
so far, but other exposure scenarios are. Reduced brain glucose metabolism by EtOH has been 
reported in various studies in both rat and man (Campbell et al. 2000; Eckardt et al., 1988; Learn 
et al., 2003; Sable et al., 2005; Volkow et al., 2012; Williams-Hemby et al., 1994). However, the 
mechanisms through which alcohol reduces brain glucose metabolism remain unclear. In human, 
y-Aminobutyric acid (GABA), an inhibitory neurotransmitter, is facilitated by alcohol (Krystal et al., 
2006) and may (in part) be responsible for the findings described in the study presented here. 
Like other GABEergic drugs, alcohol could suppress neuronal activity in human (Volkow et al., 
1995; Volkow et al., 2012). In addition, Pawlosky et al., 2010 found in rodents that elevated 
acetate concentrations in blood plasma were associated with a decrease in glucose 
phosphorylation and that infusion of alcohol decreased brain glucose uptake. Moreover, acetate is 
a good substrate for the glial monocarboxylate transporter MCT1 in rodents (Rae et al., 2012). It 
could be that during alcohol intoxication when blood acetate concentration rises, its increased 
uptake by glial cells may inhibit these cells of using glucose in favour of acetate metabolism. In 
accordance, Jiang et al. suggested with regard to human ‘that chronic heavy drinking can induce 
upregulation of blood-brain monocarboxylate transport and increase the capacity of the brain to 
oxidize acetate’ (Jiang et al., 2013, p. 1611). The combination of alcohol's GABAergic actions and 
effects of alcohol on glucose transport and phosphorylation may account for alcohol-induced 
reduction on brain glucose metabolism in rat and human (Volkow et al., 2012).  
In our study we also found that at PND 21 the 4.0% EtOH group –unlike the higher 9.0% 
EtOH dose group- showed tendency (not significant) towards increased FDG uptake activity 
compared to the control group. This tendency towards a hormetic effect of EtOH was also seen in 
the results of the body weight measurements: it was noticed that body weight gain in the 1.5% 
ethanol group tended to increase from PND 4 to PND 21 whereas this decreased in all other 
exposure groups (i.e. body weight gain was significantly affected in the 11.5% EtOH group). As 
caloric intake of EtOH is low in case of 1.5% EtOH, this ‘caloric restriction’ (CR) seemed to be 
hormetic. In fact, Turturro et al., 2000, showed that in case of nonmonotonic dose-response 
behaviour of a substance for any adverse response, CR appears to be hormetic wich results from 
body weight loss (and other potential mechanisms). The impact of BW changes can be considered 
a component of every test for hormesis (Turturro et al., 2000). The BW figures (figure 2) indeed 
displayed a nonmonotonic curve on PND 4, 7, 11, 14, 17 and 21. A nonmonotonic curve was also 
seen at test days between PND 21 and PND 70, but was mainly attributed to the fact that the 
14.0 EtOH was set on water from PND 21 onwards. Speculating about appearance of hormesis up 
to PND 21 only -considering the tendency real- the following could be deliberated on. In general, 
weaning age for rat pups is 21 days of age (NCI Animal Care and Use Committee, 2002). It could 
be that the caloric content of solid food/adult food is higher than that of the mother milk, in turn 
interfering with the caloric intake of EtOH. More studies are needed to support our arguments of 
this appearance of hormesis. 
The dose related reduction in body weight gain prior to weaning (with the 1.5% EtOH group 
excluded) and after weaning may be due to increased energy expenditure through increased EtOH 
metabolism (Larue-Achagiotis et al., 1990). 
Less prominently, brain weight in the 1.5% EtOH group on PND 21 also tended towards an 
increase rather than a decrease as observed in the other EtOH dose groups with the exception of 
the 6.5% EtOH group being larger. The result of the latter could not be explained and might be a 
fortuitous finding (SEM-values for this group were small (CE=5%)). Children with fetal alcohol 
syndrome (FAS) may have a smaller brain size (Jones et al., 2009) and lower brain weight (Jones 
and Smith, 1973) in human and also in EtOH-exposed rats (Bonthius en West, 1988; Tran et al., 
2000). So, brain weight was also assessed in this study in rats at adolescent (PND 21) and young 
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adult age (PND 70). Notice that our primary aim was to compare the body and brain weight results 
with scientific literature, because of the new –different- exposure scenario of an extended one 
generation reproduction toxicology study protocol, TG OECD 433. 
 It is also well known that alcohol may show biphasic effects, i.e., alcohol -at low dose- 
may increase sensitivity to the effects of alcohol as a positive stimulant, while -at high dose- 
increased sensitivity occurs to its negative sedative effects (Calabrese and Baldwin, 2003; Erblich 
et al., 2003; Pohorecky, 1977). Using [18F]FDG brain PET and given the circumstances of this 
feasibility study, the results pointed at a tentative biphasic effect of ethanol. In some regions, this 
tendency towards a biphasic effect seemed to be larger than in others. As such, the hippocampus 
showed a stronger increase in FDG uptake (not significant: p=0.099) for the EtOH 4.0% group on 
PND 21 (reflecting the onset of the rat’s adolescence) than the structures positioned more 
frontally of the brain base such as the frontopolar and frontal cortex and the more dorsally located 
regions of striatum and thalamus. The hippocampus develops more actively during adolescence 
(Zeigler et al., 2005) and it is this effect on FDG uptake (i.e. hyperactivity) which could reflect the 
particular sensitivity of the hippocampus during this early time window. In fact, beside the 
cerebellum, the hippocampus is one of the brain structures particularly vulnerable to alcohol 
insult (De Bellis et al., 2000; Gil-Mohapel et al., 2010; Guerri et al., 2009; Walker et al., 1992). 
Also, the significant reduction in FDG uptake (p<0.05) that was clearly visible for the frontal cortex 
on PND 35 may be related to the specific sensitivity of this brain region in adolescence (i.e. 
synaptic pruning: Zeigler et al., 2005). Brain structures like cerebellum, hippocampus and 
caudate (part of basal ganglia) are in fact particularly vulnerable to prenatal alcohol exposure 
shown in FAS individuals as reviewed by Guerri et al., 2009, McGee and Riley, 2006, Riley and 
McGee, 2005, and Spadoni et al., 2007. Moreover, frontal, parietal en temporal brain regions in 
these individuals demonstrated also to be particularly affected as reviewed by McGee and Riley, 
2006 and Spadoni et al., 2007. Although we did not selectively analyse the caudate as region of 
interest (ROI) in this study (because no clear distinction could be made between caudate and 
putamen in rat), we showed EtOH-induced reduction on brain glucose metabolism in all these 
other areas. We also did not selectively analyse the corpus callosum as region of interest (ROI) for 
PET. However, the in vivo MRI neuroimaging study in rats carried out in parallel with the study 
presented here, indeed showed EtOH-induced reduction in volume of corpus callosum (Maria 
Berk, personal communication) which is in agreement with observations in FAS individuals (Riley 
et al., 1995). 
 With regard to MA, both EtOH groups showed no statistical differences from control. The 
low TOTDM on PND 13 for the test groups compared to the other test days, and the large variation 
(SEM-bar) in the EtOH 4.0% group in particular, may reflect differences in development of eye-
opening by EtOH found at this early stage (Rianne Nederlof, personal communication). Since 
normal eye-opening occurs between PND 13-17 in rats of this Wistar strain and, in turn, affects 
MA behavior in an open arena as used for MA testing, a subtly accelerated or delayed eye-opening 
by e.g. 12 or 24 hours may reflect the disproportionate variability in activity within this group. The 
increased activity found at PND 17 for the 9.0% EtOH group compared to the control group 
originated from inability of the rat to habituate. This inability to habituate might reflect impaired 
cognitive functioning. However, since this appeared to be a temporary effect, also this impairment 
was likely to reflect changes in the development of eye opening. This was supported by the 
observed decrease in [18F]FDG brain activity in the thalamus which plays a crucial role in the 
process and relay of sensory information (Kinser and Grobstein, 2012). The biphasic effect could 
not clearly be demonstrated in the motor activity assessment. Perhaps, the tendency (p=0.133; 
not significant) towards increased motor activity of the EtOH 4.0% group and decreased activity of 
the 9.0% EtOH group at PND 60 suggested a hormetic effect. The hypoactivity of the 9.0% EtOH at 
PND 60 represented a very mild (not significant) overall depression in the habituation curve. 
Importantly, the [18F]FDG uptake clearly pointed at a persistent impairment at young adult age 
(PND 60/61), significant for the 9.0% EtOH group in PET only (i.e. hypo-activity). One of the 
functions of striatum is modulation of movement pathways (Kinser and Grobstein, 2012) and the 
suppression in striatial [18F]FDG uptake on PND 61 may in part be causally related to this 
impaired motor activity. Moreover, striatum plays a key role in cognition (for example learning) 
(Kinser and Grobstein, 2012). It can be stated that ‘motor activity in an open arena over time’ as 
measured for example in the MA test of this study, is more than just a measure of activity but 
rather also measures basic cognitive functions namely recognition (simple learning) and 
remembrance (memory) of spatial location in an open arena (Li, 2005). Habituation over time 
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during a 30min MA test session implicates such a form of very basic learning and the lack of 
habituation observed at PND 17 may be reflected by the abnormal striatial [18F]FDG uptake 
observed especially in the 9% ETOH group on PND 18. 
 Comparing motor activity and [18F]FDG brain PET imaging to detect developmental 
neurotoxicity our study showed that –under the circumstances of this study– [18F]FDG brain PET is 
a sensitive method, especially to detect effects in distinct brain regions. PET turned out more 
sensitive than MA assessment, notably with less than half of the animals for PET relative to motor 
activity testing. 
 To extrapolate our findings in a rat model with EtOH to humans, the following remains to 
be discussed. A study by Rocher et al. (2003) in baboons revealed that brain glucose metabolism 
measured with FDG-PET was highly correlated with post-mortem measures of the synaptic 
structural protein synaptophysin. The decreased FDG-PET uptake as found in our rat model with 
EtOH and found in human alcoholics could be an indicator of impaired synaptic function. This 
impaired synaptic function –in turn- might underlie the continuum of impaired intellectual function 
(Freund et al., 1988). In our rat model, such a mental impairment is further demonstrated by the 
reduction in FDG brain uptake found in the frontal cortex (involved in higher learning and planning; 
(Kinser and Grobstein, 2012) (PND 35). Mental impairment is a common feature among FASD-
children and human alcoholics (Riley and McGee, 2005; Loeber et al., 2009). Moreover, signs of 
cognitive impairment in prefrontal cortex were shown in a study by George et al., 2012 wherein 
rats had only a few months of intermittent access to alcohol. In addition, auditory startle response 
which involves the ability of learning was impaired by EtOH in our study (results not shown; Rianne 
Nederlof, personal communication). The decrease in FDG uptake found in our rat model in the 
hippocampus –key structure of learning and memory (Kinser and Grobstein, 2012)- on PND 35 
and 61, may be linked to the finding in rats and humans that alcohol causes lifelong deficits in 
‘synaptic plasticity response’, i.e. how the brains retain and adapt to experiences (Sutherland et 
al., 1997; reviewed by Berman and Hannigan, 2000; Uecker and Nadel, 1996). Prenatal exposure 
to alcohol in rhesus monkeys led to reduced dopamine function (Schneider et al, 2005) and 
reduced basal ganglia volume (Mattson et al., 1994) which concurs with our rat model with 
decreased FDG uptake in striatum (PND 18). The cerebellum is known to prominently regulate in 
man the integration of sensory perception and motor control (Kinser and Grobstein, 2012). 
Lifetime exposure to alcohol in man –as to EtOH in our rat model- may seriously damage these 
important neurological functions even in a non-reversible way. For example, parameters 
measuring neuromuscular function (e.g. gait and grip strenth) were altered in the higher dose 
groups of the main study (not shown here) running in parallel with this imaging study (Rianne 
Nederlof, personal communication). In accordance, we saw reduced FDG uptake in the cerebellum 
(PND 35 and 61) of the rat in the 9.0% EtOH group. In humans, such a reduction in FDG uptake is 
associated with impaired motor coordination as seen in patients with Wernicke's encephalopathy 
and Korsakoff's syndrome (Jung et al., 2012) and reduction in cerebellum volume (Nicolas et al., 
2000). In addition, FDG hypo-metabolism was found in thalamus, parietal and temporal regions in 
a human case of Wernicke-Korsakoff’s syndrome (Fellgiebela et al., 2003) which corresponds with 
our study PET results in rat.  
In the near future more PET scan studies with more species, both sexes, different dosing 
schemes and more test days need to be performed, in order to verify and strengthen the results in 
the present study. In addition, standard uptake value (SUV) is a measure commonly used in 
[18F]FDG PET imaging studies. However, this value has been criticized, mainly in relation to 
oncological studies (Keyes, 1995; Huang, 2000; Thie, 2004). Some alterations in the measuring 
protocol might improve the results of our study obtained with PET as well. Factors which influence 
SUV are subject size, measurement time, plasma glucose levels, plasma volume effects, SUV 
calculation and competing transport systems. With regard to subject size, it would have been 
better to correct for lean body mass or body surface area, since the SUV corrected for body weight 
still has a positive correlation with body weight (Zasadny et al., 1993; Kim et al., 1994; Sugawara 
et al., 1999). Measurement time: animals in this study were scanned 50 minutes post-injection. 
Plateau level of FDG uptake is reached after 60 minutes (Schiffer et al, 2007). Optimal sampling 
time would therefore be between 60 and 90 min after injection. Furthermore, it is important that 
time between injection and measurement is constant, since FDG uptake still decreases in this 
period. Additionally, Hamberg et al, 1994, observed that treatment of lung carcinomas changed 
the slope of tracer uptake. It might therefore be useful to obtain a dynamic scan to get information 
about the effect of the test compound on tracer uptake. Plasma glucose level can also influence 
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SUV. Fasting led to SUV almost doubled compared to SUV in high plasma glucose levels in 
patients with bronchogenic cancer (Langen et al, 1993). In addition, there is competition between 
glucose and FDG to be taken up, since both are transported through the BBB by glucose 
transporters. When plasma glucose is decreased, FDG uptake will increase (Wahl et al, 1992; 
Schiffer et al, 2007). Confounding can be prevented by determining plasma glucose levels. 
Another solution, which is less invasive and gives results with equal variation (Marsteller et al, 
2006), is to let animals fast before scanning (Turkington, 2002). Plasma volume effects: Partial 
volume is the proportion of a tomographic image containing a part of one anatomic structure and 
a part of another, so that they are indistinguishable (Huang, 2000). These effects are largest for 
small, thin irregularly shaped objects whose pixel values are most different from neighboring 
structures. Because relatively large regions were used in this study this might not have been a 
problem. It should however be born in mind that it is very important that good regions of interest 
(ROI’s) are defined. Calculation of SUV involves quantities measured with two instruments (FDG 
uptake by PET and the injected dose by a radiodosimeter). Good calibration is needed. This would 
however not influence the relation between groups (Huang, 2000). Competing transport systems: 
Zhang et al, 2009, did not observe any alterations in FDG uptake on PND 35 after ketamine 
treatment on PND 7, while in a previous study they found severe neurotoxicity after an equal 
ketamine treatment (Zou, 2009). However, they did observe an effect on [18F]-Annexin V uptake, 
which represents apoptosis. This indicates that FDG uptake alone is not able to detect all changes 
in brain development. Addition of other tracers, like [18F]-Annexin might increase sensitivity of 
PET scanning.  
Future studies are needed which vary these factors mentioned above on an experimental basis 
under different conditions in order to realize an optimal, reliable and standardized (micro)PET 
protocol. Nevertheless, our results on PET as an alternative test for MA to test brain function 
seems very promising. 
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Conclusion 
 
In conclusion, this study in a rat model with EtOH showed that PET brain imaging, 
notwithstanding the limitations mentioned, is a statistically powerful and sensitive method; same 
–or more– information could be obtained by PET compared to what is detected by the apical 
behavioral motor activity (MA) test proposed in current guidelines for developmental neurotoxicity 
testing [(U.S. Environmental Protection Agency (US EPA), 1996, 1998; Organisation for Economic 
Co-operation and Development (OECD), 2007)] and also the new test guideline for an extended 
one generation reproduction toxicology study OECD TG 433 (OECD, 2011). Using the MA test 
normal development over time could be detected. The effect of ethanol on normal neural 
development measured by MA was not significant, although a suggestive hyperactivity was found 
at PND 17 and hypoactivity at PND 60. With PET, however, information on distinct brain regions 
was obtained in addition (refinement). Moreover, PET imaging required only 5 animals per group 
(reduction), while the MA test required ten animals per group. Although PET requires cost-full 
equipment and specialized people, given the larger number of animals for behavioural testing in a 
MA test, the costs of laborious behavioural testing will be high as well, and compared to PET the 
information coming forward from MA will still be considerably less. In time, PET imaging leads to 
faster and more reliable test data once included in a regulatory setting and animal refinement and 
reduction can take place on a large scale. For example, when included in the new guideline for an 
extended one generation reproduction toxicology study OECD TG 443 (OECD, 2011) with main 
objectives to ‘evaluate specific life stages not covered by other types of toxicity studies to provide 
hazard characterization data for risk assessment while avoiding excessive use of experimental 
animals’ (Fegert et al., 2012, p. 331).  
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